Since March 27th to April 26th Skolkovo Biotechnology and Medical Cluster, Skolkovo Open University and fundamental medicine faculty hold the educational program “Pharma’s Cool 2017”. The program include innovative and technical experience of leaders of big pharmaceutical companies. On March 31 Natalia Vostokova, IPHARMA Chief Operating Officer told about planning and design of clinical trials, supposal choice, statistics calculation and regulatory authorities specifics. Vale

In October, 19th, at 11:00 AM, we will lead the webinar “Clinical trials in oncology introduction”. Register to the webinar What will we discuss at the webinar? Special aspects of clinical trials in oncology What you should pay attention on How to avoid mistakes in the monitoring data Fro whom? For drugs developers, pharmacy and biotech companies, clinical trials participants and doctors. Hosts: Valeria Azarova, IPHARMA medical advisor, PHD Elena Ibragimova, IPHARMA QA and tr

On May 5th, 2016, IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct the Phase II clinical study of the medicinal product Quisinostat. Protocol № ONC-14-NSCLCII-1-1QUI-3 "Multicenter double-blind randomized placebo-controlled Phase II clinical study with the combination of Gemcitabine, Cisplatin and Quisinostat versus Gemcitabine, Cisplatin and placebo in 1st line treatment of patients with advanced Stage IIIb-IV squamous NSCLC". The stu